

Ref: FOI/GS/ID 8344

Please reply to: FOI Administrator Trust Management Maidstone Hospital Hermitage Lane Maidstone, Kent ME16 9QQ

Email: mtw-tr.foiadmin@nhs.net

www.mtw.nhs.uk

26 July 2023

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to oesophageal and gastric cancer.

You asked:

- Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:
- a. CAPOX (Capecitabine with Oxaliplatin)
- b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
- c. Lonsurf (Trifluridine tipiracil)
- d. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- e. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- f. Any other systemic anti-cancer therapy
- g. Palliative care only
- Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:
- a. Nivolumab monotherapy or combination with Ipilimumab
- b. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
- c. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
- d. Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
- e. Any other systemic anti-cancer therapy
- f. Palliative care only
- Q3. How many patients were treated in the past 3 months for advanced/metastatic resected oesophageal cancer ONLY with:
- a. Nivolumab monotherapy or combination with Ipilimumab

- b. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
- c. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
- d. Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
- e. Any other systemic anti-cancer therapy
- f. Palliative care only
- Q4. In the past 3 months, how many patients have been initiated* on the following agents for treatment for gastric, gastro-oesophageal junction or Oesophageal cancer:
- a. Nivolumab monotherapy or in combination with Ipilimumab
- b. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
- c. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
- *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.
- Q5. Does your trust participate in any clinical trials for gastric cancer? If so, please provide the name of each trial and the number of patients taking part. Q6. Does your trust participate in any clinical trials for oesophageal cancer? If so, please provide the name of each trial and the number of patients taking part.

Trust response:

- 1.
- a. 4
- b. 0
- c. 1
- d. 0
- e. 0
- f. 17
- g. 3
- 2.
- a. 3
- b. 1
- c. 3
- d. 30
- e. 14
- f. 5
- 3.
- a. 2
- b. 1
- c. 2
- d. 11
- e. 6
- f. 0

4.

a. 1

b. 0

C.

5. & 6.

Oesophageal

1

SCOPE 2 - A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemoradiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET) (IRAS 169633) Open to recruitment - 9 patients recruited

Oesophageal and Gastric

PLATFORM - Planning treatment for oesophago-gastric cancer: a randomised maintenance therapy trial (PLATFORM Trial) (IRAS: 154429)
Recruitment currently suspended nationally by sponsor - 10 patients have been recruited